Psychedelic Stock News

MindMed Board of Directors Approves Reverse Share Split

Mind Medicine announces a reverse share split of its common shares at a 1-15 ratio. Exchange symbols will remain the same but new CUSIP numbers will be assigned by the appropriate regulators.

TSI EDITOR | 2022-08-04

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

Compass Pathways reports its Q2 2022 results. Preparing for its Phase 3 clinical trial for TRD. Net loss of $21.0 million. Cash (and equivalents) of $207.2 million.

TSI EDITOR | 2022-08-04

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa.

TSI EDITOR | 2022-07-28

Red Light Holland to Acquire Two Wellness Shops in the Netherlands: SmartShop Utrecht and SmartShop OSS

Red Light Holland acquires two of the Netherlands premier shops for psychedelic truffles and wellness products.

TSI EDITOR | 2022-07-26

Pasithea Therapeutics Awarded a Drug Development Research Grant

Pasithea Therapeutics announces being awarded a research grant of AUD $1 million (US$694,000) for its psychedelics-based research for ALS disease.

TSI EDITOR | 2022-07-14

Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs

Awakn Life Sciences announces UK government grant funding to cover 2/3rds of the costs of its Phase III clinical trial for alcohol use disorder (AUD).

TSI EDITOR | 2022-07-20

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.

TSI EDITOR | 2022-07-19

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

Better Life Pharma announces additional funding to study BETR-001 as a treatment for depression, via the Mitacs Accelerate program.

TSI EDITOR | 2022-07-06

Red Light Holland and Superstar Wiz Khalifa to Launch Naturally Occurring Psilocybin and Mushrooms Wellness Brand: Mistercap

Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland's MISTERCAP brand of psilocybin-based products.

TSI EDITOR | 2022-06-30

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

Cybin announces receipt of its "may proceed letter" from the U.S. Food and Drug Administration (FDA) regarding its Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).

TSI EDITOR | 2022-06-27